Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article More evidence on the benefits of starting DMTs sooner rather than later Assessing the impact of Ocrevus® on patients with early-stage relapsing-remitting MS Investigational agent ublituximab lowers relapse rate in two Phase III studies Study details tolebrutinib efficacy, safety profile over 48 […]

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Encouraging results from Phase II study of tolebrutinib FDA authorizes stem cell trial focused on people with mild-to-moderate MS Long-term study shows sustained efficacy, consistent safety profile for Tecfidera® No short-term increase in relapse risk from Pfizer/BioNTech COVID vaccine, study finds Government […]

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Good cause to watch for anxiety and depression in the first year after MS diagnosis The case for “starting strong” with an initial disease-modifying therapy Positive results for the investigational disease-modifying therapy ublituximab Measuring the long-term effects of relapses in MS Exploring […]

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Do you and your neurologist attach the same importance to various DMT benefits and risks? Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis MRI findings yield clues to likelihood of MS worsening in pediatric patients Young and stressed over […]